Clinical Trials
2 trialsNCT07214662 2026-06-03
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
Genentech, Inc.
Phase 1 Recruiting
NCT04337580 2026-04-13
FASN
Wake Forest University Health Sciences
Phase 2 Recruiting